Stryker [SYK] vs Dexcom [DXCM] Detailed Stock Comparison
Stryker
NYSE
Loading...
Dexcom
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Stryker wins in 17 metrics, Dexcom wins in 2 metrics, with 0 ties. Stryker appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Stryker | Dexcom | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 50.16 | 56.46 | Stryker |
| Price-to-Book Ratio | 6.81 | 12.22 | Stryker |
| Debt-to-Equity Ratio | 80.83 | 100.24 | Stryker |
| PEG Ratio | 7.26 | 39.49 | Stryker |
| EV/EBITDA | 24.84 | 33.67 | Stryker |
| Profit Margin (TTM) | 12.25% | 13.29% | Dexcom |
| Operating Margin (TTM) | 21.95% | 18.37% | Stryker |
| EBITDA Margin (TTM) | 21.95% | 18.37% | Stryker |
| Return on Equity | 14.25% | 22.83% | Dexcom |
| Return on Assets (TTM) | 7.74% | 6.08% | Stryker |
| Free Cash Flow (TTM) | $3.49B | $630.70M | Stryker |
| Dividend Yield | 0.88% | N/A | N/A |
| 1-Year Return | 13.03% | 8.44% | Stryker |
| Price-to-Sales Ratio (TTM) | 6.06 | 7.31 | Stryker |
| Enterprise Value | $158.64B | $31.09B | Stryker |
| EV/Revenue Ratio | 6.66 | 7.23 | Stryker |
| Gross Profit Margin (TTM) | 63.78% | 59.53% | Stryker |
| Revenue per Share (TTM) | $62 | $11 | Stryker |
| Earnings per Share (Diluted) | $7.53 | $1.42 | Stryker |
| Beta (Stock Volatility) | 0.91 | 1.44 | Stryker |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Stryker vs Dexcom Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Stryker | 0.90% | 1.15% | -2.22% | -2.62% | -0.96% | 6.46% |
| Dexcom | 1.24% | 2.65% | -4.52% | -5.51% | -10.58% | 3.12% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Stryker | 13.03% | 75.08% | 102.30% | 284.33% | 733.68% | 616.53% |
| Dexcom | 8.44% | -4.89% | -24.15% | 259.78% | 2,494.55% | 2,653.40% |
Performance & Financial Health Analysis: Stryker vs Dexcom
| Metric | SYK | DXCM |
|---|---|---|
| Market Information | ||
| Market Cap | $144.40B | $31.44B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 1,358,260 | 5,083,030 |
| 90 Day Avg. Volume | 1,200,997 | 3,546,350 |
| Last Close | $381.91 | $80.95 |
| 52 Week Range | $329.16 - $406.19 | $57.52 - $93.25 |
| % from 52W High | -5.98% | -13.19% |
| All-Time High | $406.19 (Jan 27, 2025) | $164.86 (Nov 15, 2021) |
| % from All-Time High | -5.98% | -50.90% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.11% | 0.15% |
| Quarterly Earnings Growth | 0.07% | 0.25% |
| Financial Health | ||
| Profit Margin (TTM) | 0.12% | 0.13% |
| Operating Margin (TTM) | 0.22% | 0.18% |
| Return on Equity (TTM) | 0.14% | 0.23% |
| Debt to Equity (MRQ) | 80.83 | 100.24 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $55.43 | $6.56 |
| Cash per Share (MRQ) | $6.45 | $7.47 |
| Operating Cash Flow (TTM) | $4.77B | $987.70M |
| Levered Free Cash Flow (TTM) | $3.49B | $425.12M |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.88% | N/A |
| Last 12-Month Dividend | $3.28 | N/A |
Valuation & Enterprise Metrics Analysis: Stryker vs Dexcom
| Metric | SYK | DXCM |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 50.16 | 56.46 |
| Forward P/E | 27.92 | 39.49 |
| PEG Ratio | 7.26 | 39.49 |
| Price to Sales (TTM) | 6.06 | 7.31 |
| Price to Book (MRQ) | 6.81 | 12.22 |
| Market Capitalization | ||
| Market Capitalization | $144.40B | $31.44B |
| Enterprise Value | $158.64B | $31.09B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 6.66 | 7.23 |
| Enterprise to EBITDA | 24.84 | 33.67 |
| Risk & Other Metrics | ||
| Beta | 0.91 | 1.44 |
| Book Value per Share (MRQ) | $55.43 | $6.56 |
Financial Statements Comparison: Stryker vs Dexcom
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SYK | DXCM |
|---|---|---|
| Revenue/Sales | $6.02B | $1.04B |
| Cost of Goods Sold | $2.18B | $447.00M |
| Gross Profit | $3.84B | $589.00M |
| Research & Development | $407.00M | $145.20M |
| Operating Income (EBIT) | $1.17B | $133.70M |
| EBITDA | $1.52B | $219.00M |
| Pre-Tax Income | $1.02B | $154.30M |
| Income Tax | $132.00M | $48.90M |
| Net Income (Profit) | $884.00M | $105.40M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SYK | DXCM |
|---|---|---|
| Cash & Equivalents | $2.32B | $904.90M |
| Total Current Assets | $13.02B | $4.55B |
| Total Current Liabilities | $7.93B | $3.04B |
| Long-Term Debt | $14.38B | $1.36B |
| Total Shareholders Equity | $20.93B | $2.27B |
| Retained Earnings | $18.86B | $1.70B |
| Property, Plant & Equipment | $1.67B | $59.10M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SYK | DXCM |
|---|---|---|
| Operating Cash Flow | $719.00M | $167.90M |
| Capital Expenditures | $-123.00M | $-87.00M |
| Free Cash Flow | $127.00M | $96.80M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | SYK | DXCM |
|---|---|---|
| Shares Short | 4.91M | 8.49M |
| Short Ratio | 4.16 | 2.71 |
| Short % of Float | 0.01% | 0.03% |
| Average Daily Volume (10 Day) | 1,358,260 | 5,083,030 |
| Average Daily Volume (90 Day) | 1,200,997 | 3,546,350 |
| Shares Outstanding | 381.40M | 390.70M |
| Float Shares | 344.60M | 389.43M |
| % Held by Insiders | 0.05% | 0.00% |
| % Held by Institutions | 0.81% | 0.99% |
Dividend Analysis & Yield Comparison: Stryker vs Dexcom
| Metric | SYK | DXCM |
|---|---|---|
| Last 12-Month Dividend | $3.28 | N/A |
| Last 12-Month Dividend Yield | 0.88% | N/A |
| 3-Year Avg Annual Dividend | $3.09 | N/A |
| 3-Year Avg Dividend Yield | 0.27% | N/A |
| 3-Year Total Dividends | $9.26 | N/A |
| Ex-Dividend Date | Mar 31, 2025 | N/A |